Ueno H, et al. - Researchers determined the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test. In addition, they investigated the glucose-lowering mechanisms of ipragliflozin. In this study, by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement, ipragliflozin improved glycemic control. Findings suggested that ipragliflozin could offer benefits for patients with obesity and type 2 diabetes mellitus.